Clinical trials: Cancer Treatment
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
The primary objectives of this study are to determine the maximum tolerated dose (MTD) or optimal biologic dose (OBD) and safety profile of CAT-8015 in participants with relapsed or refractory advanced B-cell NHL (diffuse large…
- Trial name
- NCT01030536
- Testing
- CAT-8015 20 mcg/kg, CAT-8015 30 mcg/kg, CAT-8015 40 mcg/kg
- Where
- 8 sites in United States, Poland
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Neuroendocrine Tumors
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors…
- Trial name
- NCT02592707
- Testing
- Satoreotide tetraxetan, Amino acid solution, Antiemetic
- Where
- 9 sites in United States, Australia and 6 more
- Volunteers
- 40 people
- Sponsor
- Ipsen
Stomach Neoplasms
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and antitumor response of ramucirumab in combination with platinum/fluoropyrimidine regimens in Japanese participants with advanced…
- Trial name
- NCT02359058
- Testing
- Ramucirumab, Capecitabine, Cisplatin
- Where
- 4 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Pancreatic Tumours, Midgut Neuroendocrine Tumours
Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg
This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine…
- Trial name
- CLARINET FORTE (NCT02651987)
- Testing
- Lanreotide autogel 120 mg
- Where
- 32 sites in Belgium, Denmark and 8 more
- Volunteers
- 99 people
- Sponsor
- Ipsen
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort…
- Trial name
- NCT07217184
- Testing
- Belantamab mafodotin, Isatuximab
- Where
- 19 sites in United States, Australia and 9 more
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Carcinoma of the Head and Neck
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
The primary objective of this study was to evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in adults with recurrent or metastatic…
- Trial name
- MASTERKEY232 (NCT02626000)
- Testing
- Talimogene Laherparepvec, Pembrolizumab
- Where
- 33 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Amgen
Ovarian Neoplasms
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
This is an international, randomized phase II trial. The aim is to assess the efficacy and the safety of BI 6727 Versus investigator's best choice single agent cytotoxic in recurrent third and fourth lines platinum…
- Trial name
- NCT01121406
- Testing
- Paclitaxel, Gemcitabine, Topotecan
- Where
- 31 sites in Belgium, France and 3 more
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
Colorectal Cancer
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic…
- Trial name
- NCT03555149
- Testing
- Regorafenib, Atezolizumab, Imprime PGG
- Where
- 15 sites in United States, Australia and 3 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies
A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)
The purpose of this study is to evaluate the safety of TAK-164 and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and schedule.
- Trial name
- NCT03449030
- Testing
- TAK-164, 89Zr-TAK-164
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
The primary objective of this trial is to compare the survival of patients with advanced non-small cell lung cancer (NSCLC) treated with weekly Taxoprexin in combination with carboplatin to those treated with paclitaxel plus…
- Trial name
- NCT00243867
- Testing
- Taxoprexin, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 518 people
- Sponsor
- American Regent, Inc.
NSCLC Stage IV
MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC
Assess the Efficacy and Safety of MYL-1402O Compared with Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer
- Trial name
- NCT04633564
- Testing
- Bevacizumab as MYL-1402O, Bevacizumab as Avastin
- Where
- 102 sites in Belarus, Bosnia and Herzegovina and 15 more
- Volunteers
- 671 people
- Sponsor
- Mylan Pharmaceuticals Inc
Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.
- Conditions
- Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
- Trial name
- NCT03948763
- Testing
- V941, Pembrolizumab
- Where
- 26 sites in United States, Australia and 5 more
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Barrett's Esophagus
Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation
This study is designed to evaluate the effect of dexlansoprazole once daily (QD) and twice daily (BID) dosing on the recurrence of intestinal metaplasia (IM) in participants who achieved complete eradication of Barrett's…
- Trial name
- NCT02162758
- Testing
- Dexlansoprazole
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Takeda
Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent /…
- Conditions
- Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
- Trial name
- STAR-TOR (NCT00700258)
- Testing
- Temsirolimus, Sunitinib, Axitinib
- Where
- 77 sites in Germany
- Volunteers
- 1,520 people
- Sponsor
- Pfizer
Prostatic Neoplasms
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer (mHRPC).
- Trial name
- NCT00137436
- Testing
- Docetaxel, Prednisone, SU011248
- Where
- 24 sites in United States
- Volunteers
- 93 people
- Sponsor
- Pfizer
Non-Hodgkin's Lymphoma
A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas
This Phase Ib/II, open-label, multicenter trial is designed to evaluate the safety, pharmacokinetics, and efficacy of dulanermin when combined with rituximab in subjects with follicular, CD20+, B-cell Non-Hodgkin's Lymphoma (NHL)…
- Trial name
- NCT00400764
- Testing
- Dulanermin, Rituximab
- Volunteers
- 72 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
- Trial name
- NCT00865709
- Testing
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Where
- 116 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Prostatic Neoplasms, Castration-Resistant
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
The purpose of this real-world study is to learn about the effects of 2 study medicines called enzalutamide and abiraterone used to treat metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT05968599
- Testing
- Enzalutamide, Abiraterone acetate
- Where
- United States
- Volunteers
- 2,731 people
- Sponsor
- Pfizer
Dupuytren's Contracture
AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture
This was a Phase 3, double-blind, randomized, placebo-controlled study conducted in the United States. Subjects with a diagnosis of Dupuytren's contracture in a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint…
- Trial name
- CORD-I (NCT00528606)
- Testing
- collagenase clostridium histolyticum
- Where
- 15 sites in United States
- Volunteers
- 308 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Carcinoma, Non-Small-Cell Lung
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Evaluation of gemcitabine and cisplatin in combination with either sorafenib or placebo for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- NEXUS (NCT00449033)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Gemcitabine, Cisplatin
- Where
- 122 sites in Austria, Belgium and 16 more
- Volunteers
- 904 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.